反応式
[CH2:1]([C:3]1[CH:7]=[C:6]([C:8]23[CH2:15][CH2:14][CH2:13][N:12]2[CH2:11][CH2:10][CH2:9]3)[O:5][N:4]=1)[CH3:2].[ClH:16]>CCOCC>[ClH:16].[CH2:1]([C:3]1[CH:7]=[C:6]([C:8]23[CH2:15][CH2:14][CH2:13][N:12]2[CH2:11][CH2:10][CH2:9]3)[O:5][N:4]=1)[CH3:2]参加物
4
実験手順
7a-(3-ethyl-5-isoxazolyl)-hexahydro-1H-pyrrolizine (265 mg, 1.30 mmol, from step 13b) was dissolved in Et2O, and Et2O saturated with HCl (g) was added. The solvent was removed, and the precipitate was recrystallized from methanol/ethanol to afford the title compound as a white solid: mp 139°-140° C.; 1H NMR D2O, 300 MHz) δ1.23 (t, J=7.5 Hz, 3H), 2.17-2.40 (m, 6H), 2.58-2.75 (m, 4H), 3.29-3.38 (m, 2H), 3.69-3.77 (m, 2H), 6.64 (s, 1H); MS (CI/NH3) m/z: 207 (M+H)+ ; Anal. Calcd for C12H18N2O.HCl: C, 59.38; H, 7.89; N, 11.54. Found: C, 59.44; H, 7.94; N, 11.48.
後処理
- customThe solvent was removed
- customthe precipitate was recrystallized from methanol/ethanol
出典と根拠
- ORDレコード
- ord-6a17fe06ca0a4559821af5872f757c00
- 出典データセット
- uspto-grants-1998_03
- 特許番号
- US05733912
関連ノート
読み込み中…